# Safinamide

## Equfina 50mg

| TAH Drug Code      | [OEQU](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OEQU                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Parkinson disease: Adjunctive treatment to carbidopa/levodopa in patients with Parkinson disease experiencing "off" episodes.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Dosing             | Parkinson disease: Oral 50 mg once daily (in combination with carbidopa/levodopa); after 2 weeks may increase to 100 mg once daily (in combination with carbidopa/levodopa) based on response and tolerability. Discontinuation of therapy: Decrease dose to 50 mg for one week before discontinuing therapy.                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Contraindications  | Hypersensitivity to safinamide or any component of the formulation. Severe hepatic impairment (Child-Pugh class C) Concomitant use of methylphenidate, amphetamine, and their derivatives, or dextromethorphan. Concomitant use with or within 2 weeks of other monoamine oxidase inhibitors or other drugs that are potent inhibitors of monoamine oxidase (including linezolid), opioids (eg, meperidine, methadone, propoxyphene, tramadol), serotonin-norepinephrine reuptake inhibitors, tricyclic, tetracyclic, or triazolopyridine antidepressants, cyclobenzaprine, St John's wort. Albinism, retinal degeneration, uveitis, inherited retinopathy or any active retinopathy (including severe progressive diabetic retinopathy). |
| Adverse Effects    | Common: Nausea (3-6%), Dyskinesia (17-21%), Insomnia (1-4%), Falls (4-6%) Serious: Hypertension (5-7%), Hallucinations, Impulse control disorder, Serotonin syndrome >10%: Dyskinesia (17-21%) 1-10%: Cardiovascular: Hypertension (including exacerbation of hypertension: 5-7%), orthostatic hypotension (2%), Dyspepsia (2%), nausea (6%), Increased serum alanine aminotransferase (5-7%), increased serum aspartate aminotransferase (6-7%), Anxiety (2%), falling (6%), insomnia (4%), Cough (2%) Frequency not defined: Nervous system: Impulse control disorder, sudden onset of sleep Postmarketing: Hypersensitivity reaction, Headache                                                                                         |
| Pregnancy          | No (Limited) Human Data â€“ Animal Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| More Info          | [UpToDate](https://www.uptodate.com/contents/safinamide-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

